Similar companies
Income Statement (USD)
Q1 '24 | QoQ | |
---|---|---|
Revenue | 3.79B | 3.5% |
Gross Profit | 2.65B | 2.7% |
Cost of Revenue | 2.8B | 1.3% |
Operating expense | 1.97B | 1.1% |
Net Income | 492M | 2.2% |
EBITDA | 890M | 14.5% |
Balance Sheet (USD)
Q1 '24 | QoQ | |
---|---|---|
Total Assets | 36.7B | 4.4% |
Total Liabilities | 16.7B | 5.6% |
Total Equity | 19.9B | 3.3% |
Shares Outstanding | 1.47B | 0.2% |
Cash Flow (USD)
Q1 '24 | QoQ | |
---|---|---|
Cash from operations | 164M | 82.9% |
Cash from investing | -285M | 72.9% |
Cash from financing | 1.57B | 10360% |
EPS
Financial Highlights for Boston Scientific in Q1 '24
Boston Scientific reported a revenue of 3.79B, which is a 3.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.65B, marking a 2.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 2.8B, a 1.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 1.97B, showing a -1.1% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 492M, showing a -2.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 890M, showing a 14.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Boston Scientific faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income.